A progressively enlarging cerebellar hematoma concurrent with T-DM1 treatment. Case report

Trastuzumab emtansine, an antibody –drug conjugate commonly abbreviated as T-DM1, is accepted as an effective therapy for trastuzumab-resistant metastatic HER2-positive breast cancer. T-DM1 significantly increases progression-free and overall survival when compared to lapatinib plus capecitabine in patients with HER2-positive breas t cancer previously treated with trastuzumab and a taxane. Among the common side effects related to T-DM1, thrombocytopenia and mucosal hemorrhage are seen, although they are infrequently judged to be clinically significant.
Source: World Neurosurgery - Category: Neurosurgery Authors: Tags: Case Report Source Type: research